Multiple myeloma patients with side effects of subcutaneous bortezomib need to be treated aggressively with symptomatic therapy and delayed chemotherapy if necessary.
The common side effects of subcutaneous bortezomib injection in patients with multiple myeloma are nerve damage, myelosuppression, decreased immunity, pneumonia, and herpes zoster.
It is necessary to correspondingly give nutritional nerve (such as B vitamins, etc.), the application of painkillers, anti-infection (empirical selection of antibiotics, or according to the results of blood culture and sputum culture selection of antibiotics, and, if necessary, antiviral therapy such as acyclovir and other drugs, to prevent the occurrence of herpes zoster), the stimulation of hematopoiesis, the elevation of leukocytes, platelet elevation, the transfusion of blood products and other treatments, to ensure the safety of the patient’s life and the quality of life.
If the patient has high side effects and slow recovery after symptomatic treatment, the drugs in the chemotherapy regimen can be appropriately reduced or the interval between bortezomib doses can be extended, or the treatment regimen can be changed.